An observational study in Crohn Disease, sponsored by Xian-Janssen Pharmaceutical Ltd.. Completed at 3 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-26.
Sponsored by Xian-Janssen Pharmaceutical Ltd. (part of Johnson & Johnson) · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 63 studies in Crohn Disease by Johnson & Johnson — 16 open to participants now, 23 under way, 10 of them phase 3. Crohn Disease · Johnson & Johnson.
Among the 63 studies in Crohn Disease by Johnson & Johnson, this one is the 11th largest by enrollment of the 22 observational ones that give a count, is one of 2 that started in 2023, is one of 22 observational ones, and was the 48th registered.
1,994 studies on the registry are indexed under Crohn Disease; 477 are open to participants now.
Browse Crohn Disease studies →16 of the 63 studies in Crohn Disease by Johnson & Johnson are open now, in 12 countries. Recruiting first, the newest first:
Janssen Research & Development, LLC · Sites in United States
Ages 18+ · Women only
Janssen-Cilag Pharma GmbH · Sites in Austria
Ages 18+
Janssen Research & Development, LLC · Sites in United States, Argentina, Australia and 27 more countries
Ages 18+
Janssen Research & Development, LLC · Sites in Saudi Arabia
Ages 18+
Janssen Research & Development, LLC · Sites in United States, Austria, Belgium and 14 more countries
Ages 18+
By country, each count listing its studies:
Of the 353 Crohn Disease studies recruiting now, 155 (44%) set no upper age limit and 143 (41%) stop at 75 or younger; 94 take children under 18; 56 take healthy volunteers.
This study: 18 Years and older · all sexes.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
63 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 10 · Phase 3 26 · Phase 4 5
First in 1995; this study’s year is marked. 2 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 200 is close to the median of 184 across 646 observational studies indexed under Crohn Disease.
Median enrollment 189 across the 40 interventional studies, 200 across the 22 observational. Of the 38 that completed or were terminated, 16 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Xian-Janssen Pharmaceutical Ltd., one of the names counted as Johnson & Johnson. Under that name alone:
Xian-Janssen Pharmaceutical Ltd. is the lead sponsor of 36 studies on the registry; 2 are open to participants now.
6 of the studies in Crohn Disease by Johnson & Johnson that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05347095Phase 3Janssen-Cilag Ltd.A Study of Guselkumab in Participants With Fistulizing, Perianal Crohn's Disease | 2027-03-25 |
| NCT06408935Phase 3Janssen-Cilag Ltd.Transmural Healing and Disease-Modifying Effect of Guselkumab in Crohn's Disease Patients | 2027-06-08 |
| NCT05092269Phase 3Janssen Research & Development, LLCA Long-term Extension Study of Ustekinumab in Pediatric Participants | 2027-09-29 |
| NCT05923073Phase 3Janssen Research & Development, LLCA Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease | 2027-10-27 |
| NCT07654751Janssen Research & Development, LLCA Remotely Conducted Study to Assess Concentration of TREMFYA in Breast Milk of Lactating Women Who Are Receiving TREMFYA Therapeutically | 2027-08-31 |
Add all 6 to your calendar (.ics) → With an account.
Among the 63 studies in Crohn Disease by Johnson & Johnson, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Bio-naive participants are defined as the participants who previously have not received any biologics for Crohn's Disease (CD).The purpose of this retrospective study is to describe the endoscopic remission at week 24 among bio-naive participants with CD treated with ustekinumab in China.
Study population will consist of bio-naive participants who initiated ustekinumab therapy for the first time between 20 May 2020 and 16 September 2022.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants with CD from inflammatory bowel disease (IBD) database who received ustekinumab from 20 May 2020 to 16 September 2022 in the real-world setting in China will be observed in the study. Only data available per routine clinical practice will be collected within this study.
Drug: Ustekinumab
No interventions will be administered as a part of this study. Participants received ustekinumab as per their routine clinical practice.
Percentage of Participants With Endoscopic Remission at Week 24
Endoscopic remission: simple endoscopic score for crohn's disease (SES-CD) less than or equal to (\<=) 2, total SES-CD \<=4, a decrease in total SES-CD greater than or equal to (\>=) 2 from baseline, and no subtotal SES-CD \>1 for each endoscopic parameter (for isolated ileal, ileocolonic and isolated colonic CD), rutgeerts score \<=i1 (for post-operation CD). SES-CD: assesses disease severity based on 4 endoscopic parameters across 5 ileocolonic segments. Total SES-CD = 0 to 56,higher scores = more severe disease. Rutgeerts score: assess postoperative disease recurrence with no lesions (i0); \<=5 aphthous lesions (i1); \>5 aphthous ulcers with normal intervening mucosa/patchy areas of larger lesions/lesions confined to ileocolic anastomosis (i2); diffuse aphthous ileitis and diffusely inflamed mucosa (i3); diffuse inflammation with large ulcers, nodules, and/or stenosis (i4).
Time frame: Week 24
Percentage of Participants With Endoscopic Response at Week 24
Endoscopic response is defined as \>50 percent (%) decrease from baseline in total SES-CD. The SES-CD is a scoring system to assess disease severity in participants with CD. The SES-CD score is based on the evaluation of 4 endoscopic components: size of ulcers, surface ulceration, affected surface size, and presence of luminal narrowing across 5 predefined ileocolonic segments (ileum, right colon, transverse colon, left colon and rectum). Each component score= 0 to 3 for each segment with total SES-CD score ranges from 0 to 56, where higher scores indicates more severe disease.
Time frame: Week 24
Percentage of Participants With Clinical Remission at Week 24
Clinical remission is achieved when total crohn's disease activity index (CDAI) \<150 or total of harvey-bradshaw index (HBI) score \<5. CDAI assesses CD based on variables: extra-intestinal manifestations, abdominal mass, weight, hematocrit, total number of liquid stools, abdominal pain, use of antidiarrheal drug(s) and general well-being. CDAI score: asymptomatic remission: \<150, mild: 150-220, moderate: 221-450, severe: \>450. HBI parameters: general well-being (0-4, higher score means lower well-being), abdominal pain (0-3, higher score means more severe pain), number of liquid stools per day (score 1 per movement), abdominal mass (0=none, 1=dubious, 2=definite, 3=definite and tender) and complications (score 1 per item). Total score is sum of individual parameters. Score ranges from 0 to no pre-specified maximum score as it depends on number of complications and liquid stools per day. HBI score: \<5 (remission), 5-7 (mild disease), 8-16 (moderate disease) and \>16 (severe disease).
Time frame: Week 24
Percentage of Participants With Clinical Response at Week 24
Clinical response is defined as decrease in total CDAI score from \>=100 or a CDAI score \<150 or decrease in total HBI score \>=3 from baseline. CDAI assesses CD based on variables: extra-intestinal manifestations, abdominal mass, weight, hematocrit, total number of liquid stools, abdominal pain, use of antidiarrheal drug(s) and general well-being. CDAI score: asymptomatic remission: \<150, mild: 150-220, moderate: 221-450, severe: \>450. HBI parameters: general well-being (0-4, higher score means lower well-being), abdominal pain (0-3, higher score=more severe pain), number of liquid stools per day (score 1 per movement), abdominal mass (0=none, 1=dubious, 2=definite, 3=definite and tender) and complications (score 1 per item). Total score is sum of individual parameters. Score ranges from 0 to no pre-specified maximum score as it depends on number of complications and liquid stools per day. HBI score: \<5 (remission), 5-7 (mild disease), 8-16 (moderate disease) and \>16 (severe disease).
Time frame: Week 24
Percentage of Participants With Steroid-free Clinical Remission at Week 24
Steroid-free clinical remission is achieved when total CDAI score \<150 or total HBI score \<5, without use of any steroid preparations. CDAI assesses CD based on variables: extra-intestinal manifestations, abdominal mass, weight, hematocrit, total number of liquid stools, abdominal pain, use of antidiarrheal drug(s) and general well-being. CDAI score: asymptomatic remission: \<150, mild: 150-220, moderate: 221-450, severe: \>450. HBI parameters: general well-being (0-4, higher score=lower well-being), abdominal pain (0-3, higher score=more severe pain), number of liquid stools per day (score 1 per movement), abdominal mass (0=none, 1=dubious, 2=definite, 3=definite and tender) and complications (score 1 per item). Total score is sum of individual parameters. Score ranges from 0 to no pre-specified maximum score as it depends on the number of liquid stools per day and number of complications. HBI score: \<5 (remission), 5-7 (mild disease), 8-16 (moderate disease) and \>16 (severe disease).
Time frame: Week 24
Percentage of Participants With Steroid-free Clinical Response at Week 24
Steroid-free clinical response: decrease in total CDAI score \>=100 or total HBI score \>=3 from baseline, without use of any steroid preparations. CDAI assesses CD based on variables: extra-intestinal manifestations, abdominal mass, weight, hematocrit, total number of liquid stools, abdominal pain, use of antidiarrheal drug(s) and general well-being. CDAI score: asymptomatic remission: \<150, mild: 150-220, moderate: 221-450, severe: \>450. HBI parameters: general well-being (0-4, higher score=lower well-being), abdominal pain (0-3, higher score=more severe pain), number of liquid stools per day (score 1 per movement), abdominal mass (0=none, 1=dubious, 2=definite, 3=definite and tender) and complications (score 1 per item). Total score is sum of individual parameters. Score ranges from 0 to no pre-specified maximum score as it depends on number of complications and liquid stools per day. HBI score: \<5 (remission), 5-7 (mild disease), 8-16 (moderate disease) and \>16 (severe disease).
Time frame: Week 24
Change From Baseline in C-Reactive Protein (CRP) at Week 24
Change from baseline in CRP at Week 24 will be reported.
Time frame: Baseline and Week 24
Change From Baseline in Fecal Calprotectin at Week 24
Change from baseline in fecal calprotectin at Week 24 will be reported.
Time frame: Baseline and Week 24
Percentage of Participants With Disease Progression
Disease progression is defined as the first occurrence of CD complications, or CD-related surgery and hospitalization from index date to death or end of study. Index date is defined as the date of initiating ustekinumab treatment for the first time. CD-related surgery is defined as the first occurrence of any CD-related intestinal and perianal procedures. CD-related hospitalization is defined as the first occurrence of any CD-related admission, with causes including disease relapse, complication, and drug side effects, except for CD-related surgery.
Time frame: From index date up to death or end of study (up to 34.4 months)
Time to Disease Progression
Disease progression is defined as the first occurrence of CD complications, or CD-related surgery and hospitalization from index date to death or end of study. Index date is defined as the date of initiating ustekinumab treatment for the first time. CD-related surgery is defined as the first occurrence of any CD-related intestinal and perianal procedures. CD-related hospitalization is defined as the first occurrence of any CD-related admission, with causes including disease relapse, complication, and drug side effects, except for CD-related surgery.
Time frame: From index date up to death or end of study (up to 34.4 months)
Percentage of Participants With Ustekinumab Therapy Switch During the Observational Period to Other Therapy
Percentage of participants who will switch to other therapy will be reported. Therapy switch is defined as switching to other biologic therapy from index date to death or end of study. Index date is defined as the date of initiating ustekinumab treatment for the first time.
Time frame: From index date up to death or end of study (up to 34.4 months)
Percentage of Participants With Reasons for Ustekinumab Therapy Switch to Other Therapy
Percentage of participants with reasons for ustekinumab therapy switch to other therapy will be reported. Therapy switch is defined as switching to other biologic treatments from index date to death or end of study. Index date is defined as the date of initiating ustekinumab treatment for the first time.
Time frame: From index date up to death or end of study (up to 34.4 months)
Percentage of Participants With Ustekinumab Therapy Discontinuation
Percentage of participants with ustekinumab therapy discontinuation will be reported. Therapy discontinuation is defined as having a ustekinumab therapy gap of greater than or equal to (\>=) 120 days without treatment switch or intravenous re-induction from index date to death or end of study. Index date is defined as the date of initiating ustekinumab treatment for the first time.
Time frame: From index date up to death or end of study (up to 34.4 months)
Percentage of Participants With Reasons for Ustekinumab Therapy Discontinuation
Percentage of participants with reasons for ustekinumab therapy discontinuation will be reported. Therapy discontinuation is defined as having a ustekinumab therapy gap of \>=120 days without treatment switch or intravenous re-induction from index date to death or end of study. Index date is defined as the date of initiating ustekinumab treatment for the first time.
Time frame: From index date up to death or end of study (up to 34.4 months)
Time to Ustekinumab Therapy Switch or Discontinuation
Time to ustekinumab therapy switch or discontinuation will be reported. Therapy switch is defined as switching to other biologic therapy from index date to death or end of study. Therapy discontinuation is defined as having a ustekinumab therapy gap of \>=120 days without treatment switch or intravenous re-induction from index date to death or end of study. The time to therapy switch or discontinuation is defined as follows: 1) For participants with an event date, it is calculated as the difference between the event date and index date, adding 1. 2) For participants without an event date, it is calculated as the difference between the end of the observation date (death/end of study) and the index date, adding 1; this time is a censoring time. The event date is the initiation date of therapy switch or discontinuation, whichever happens first. Index date is defined as the date of initiating ustekinumab treatment for the first time.
Time frame: From index date up to death or end of study (up to 34.4 months)
Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Percentage of participants with AEs and SAEs will be reported. An AE is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product. SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Index date is defined as the date of initiating ustekinumab treatment for the first time.
Time frame: From index date up to death or end of study (up to 34.4 months)
Percentage of Participants With Each Adverse Event (AE)
Percentage of participants with each AE will be reported. An AE is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product. Index date is defined as the date of initiating ustekinumab treatment for the first time.
Time frame: From index date up to death or end of study (up to 34.4 months)
Duration of Each Adverse Event (AE)
Duration of each AE will be reported. Duration of each AE's is defined as time from onset of AE to end date of each AE or till the end of the study. An AE is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product. Index date is defined as the date of initiating ustekinumab treatment for the first time.
Time frame: From index date up to death or end of study (up to 34.4 months)
Percentage of Participants With Each AE's Outcome
Percentage of participants with each AE's outcome will be reported. Each AE's outcome includes recovered/resolved, recovered/resolved with sequelae, recovering/resolving, not recovered/not resolved, fatal, and unknown. An AE is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product. Index date is defined as the date of initiating ustekinumab treatment for the first time.
Time frame: From index date up to death or end of study (up to 34.4 months)
Percentage of Participants With Ustekinumab Therapy Switch or Discontinuation due to AEs
Percentage of participants with ustekinumab therapy switch or discontinuation due to AEs will be reported. Therapy switch is defined as switching to other biologic therapy from index date to death or end of study. Therapy discontinuation is defined as having a ustekinumab therapy gap of \>=120 days without treatment switch or intravenous re-induction from index date to death or end of study. Index date is defined as the date of initiating ustekinumab treatment for the first time. An AE is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product.
Time frame: From index date up to death or end of study (up to 34.4 months)
Plan to share: No
No publications or documents are linked to this record.
Ran from Oct 2023 to primary completion in Jun 2024, 7 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Xian-Janssen Pharmaceutical Ltd. →